OneDigital Investment Advisors LLC Cuts Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

OneDigital Investment Advisors LLC lessened its position in Agilent Technologies, Inc. (NYSE:A) by 1.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,080 shares of the medical research company’s stock after selling 88 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Agilent Technologies were worth $903,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Crewe Advisors LLC grew its stake in Agilent Technologies by 114.8% during the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 101 shares in the last quarter. Livelsberger Financial Advisory purchased a new stake in shares of Agilent Technologies in the third quarter valued at approximately $28,000. Ridgewood Investments LLC acquired a new stake in shares of Agilent Technologies in the second quarter valued at approximately $29,000. Ashton Thomas Securities LLC purchased a new position in Agilent Technologies during the third quarter worth approximately $31,000. Finally, Fortitude Family Office LLC boosted its stake in Agilent Technologies by 68.3% during the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock worth $35,000 after buying an additional 95 shares during the last quarter.

Agilent Technologies Stock Performance

Shares of A stock opened at $125.70 on Wednesday. Agilent Technologies, Inc. has a 52 week low of $112.39 and a 52 week high of $155.35. The firm has a 50 day moving average of $138.26 and a two-hundred day moving average of $137.83. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $36.12 billion, a PE ratio of 26.08, a P/E/G ratio of 5.59 and a beta of 1.07.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.26 by $0.06. The firm had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. Agilent Technologies’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.43 EPS. On average, research analysts predict that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st were paid a dividend of $0.236 per share. The ex-dividend date was Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.75%. Agilent Technologies’s payout ratio is 19.50%.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Barclays lifted their price target on Agilent Technologies from $135.00 to $145.00 and gave the stock an “underweight” rating in a report on Tuesday, October 15th. TD Cowen lifted their price target on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Bank of America lifted their target price on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Wells Fargo & Company assumed coverage on Agilent Technologies in a report on Tuesday, August 27th. They set an “overweight” rating and a $157.00 price target for the company. Finally, Stifel Nicolaus restated a “buy” rating and issued a $151.00 price objective on shares of Agilent Technologies in a report on Monday, August 26th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $144.36.

Insider Buying and Selling

In other news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the completion of the transaction, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at approximately $5,801,595. This represents a 19.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the transaction, the chief executive officer now owns 24,118 shares in the company, valued at approximately $3,497,110. The trade was a 7.51 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,995 shares of company stock worth $1,739,510.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.